A first-in-human study of ARO-033 for adults with wet AMD
Part of Eyes & vision clinical trials.
This study tests a new medicine called ARO-033 for people with age-related macular degeneration (AMD), a common eye condition that can cause vision loss. The trial will see if the medicine is safe and how it affects the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old if you have AMD, or 18 to 65 if you are a healthy volunteer.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study and for 90 days after.
- Your body mass index (BMI) must be between 18 and 35.
- You must have a confirmed diagnosis of AMD in both eyes (if you are in the AMD group).
- You must be free of HIV, hepatitis B, or active hepatitis C.
- You must not have uncontrolled high blood pressure or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.